The Pathophysiology of Uremia

Chronic Kidney Disease, Dialysis, and Transplantation

Volumn , Issue , 2010, Pages 251-264

  Abramowitz, Matthew K ^a   Meyer, Timothy W ^b,c   Hostetter, Thomas H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA Palo Alto HCS ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882480784     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0987-2.00018-2     Document Type: Chapter

References (240)

1. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003, 63:1934-1943.
2. Bergstrom J. Uremic toxicity. Nutritional Management of Renal Disease 1997, 97-190. Williams & Wilkins, Baltimore. J.D. Kopple, S.G. Massry (Eds.).
3. Depner T.A. Uremic toxicity: urea and beyond. Sem. Dialysis 2001, 14:246-251.
4. Niwa T. Mass spectrometry in the search for uremic toxins. Mass Spectrom. Rev. 1997, 16:307-332.
5. Teschan P. Studies in the pathogenesis of uremic encephalopathy. Uremia 1972, 32-36. Georg Thieme Verlag, Stuttgart. G. Berlyne, B. Burton (Eds.).
6. Johnson W.J., Hagge W.W., Wagoner R.D., et al. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin. Proc. 1972, 47:21-29.
7. Schreiner G., Maher J. Biochemistry of Uremia. Uremia 1960, 55-85. Charles Thomas, Springfield.
8. Richards P., Brown C.L. Urea metabolism in an azotaemic woman with normal renal function. Lancet 1975, 2:207-209.
9. Conte G., Dal Canton A., Terribile M., et al. Renal handling of urea in subjects with persistent azotemia and normal renal function. Kidney Int. 1987, 32:721-727.
10. Hsu C.H., Kurtz T.W., Massari P.U., et al. Familial azotemia. Impaired urea excretion despite normal renal function. N. Engl. J. Med. 1978, 298:117-121.
11. Final report of the safety assessment of Urea. Int. J. Toxicol. 2005, 24(Suppl. 3):1-56.
12. Noris M., Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies?. Blood 1999, 94:2569-2574.
13. Eknoyan G., Wacksman S.J., Glueck H.I., et al. Platelet function in renal failure. N. Engl. J. Med. 1969, 280:677-681.
14. Kraus L.M., Kraus A.P. Carbamoylation of amino acids and proteins in uremia. Kidney Int. Suppl. 2001, 78:S102-S107.
15. Tarif N., Shaykh M., Stim J., et al. Carbamylated hemoglobin in hemodialysis patients. Am. J. Kidney Dis. 1997, 30:361-365.
16. Veeneman J.M., Kingma H.A., Stellaard F., et al. Comparison of amino acid oxidation and urea metabolism in haemodialysis patients during fasting and meal intake. Nephrol. Dial. Transplant. 2004, 19:1533-1541.
17. Walser M. Urea metabolism in chronic renal failure. J. Clin. Invest. 1974, 53:1385-1392.
18. Davies S., Spanel P., Smith D. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Kidney Int. 1997, 52:223-228.
19. Narasimhan L.R., Goodman W., Patel C.K. Correlation of breath ammonia with blood urea nitrogen and creatinine during hemodialysis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4617-4621.
20. Nagata Y., Akino T., Ohno K., et al. Free D-amino acids in human plasma in relation to senescence and renal diseases. Clin. Sci. (Lond.) 1987, 73:105-108.
21. Bruckner H., Hausch M. Gas chromatographic characterization of free D-amino acids in the blood serum of patients with renal disorders and of healthy volunteers. J. Chromatogr. 1993, 614:7-17.
22. Friedman M. Chemistry, nutrition, and microbiology of D-amino acids. J. Agric. Food Chem. 1999, 47:3457-3479.
23. Silbernagl S., Volker K., Dantzler W.H. D-Serine is reabsorbed in rat renal pars recta. Am. J. Physiol. 1999, 276:F857-F863.
24. Hasegawa H., Matsukawa T., Shinohara Y., et al. Role of renal D-amino-acid oxidase in pharmacokinetics of D-leucine. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E160-E165.
25. Nagata Y., Masui R., Akino T. The presence of free D-serine, D-alanine and D-proline in human plasma. Experientia 1992, 48:986-988.
26. Young G., Kendall S., Brownjohn A. D-amino acids in chronic renal failure and the effects of dialysis and urinary losses. Amino Acids 1994, 6:283-293.
27. Fuchs S.A., Berger R., Klomp L.W., et al. D-amino acids in the central nervous system in health and disease. Mol. Genet. Metab. 2005, 85:168-180.
28. Nagata Y., Konno R., Niwa A. Amino acid levels in D-alanine-administered mutant mice lacking D-amino acid oxidase. Metabolism 1994, 43:1153-1157.
29. Hashimoto A., Nishikawa T., Konno R., et al. Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase. Neurosci. Lett. 1993, 152:33-36.
30. Harper A.E., Benevenga N.J., Wohlhueter R.M. Effects of ingestion of disproportionate amounts of amino acids. Physiol. Rev. 1970, 50:428-558.
31. Adibi S.A. Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Am. J. Physiol. 1997, 272:E723-E736.
32. Daniel H., Herget M. Cellular and molecular mechanisms of renal peptide transport. Am. J. Physiol. 1997, 273:F1-F8.
33. Druml W., Lochs H., Roth E., et al. Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. Am. J. Physiol. 1991, 260:E280-E285.
34. Verroust P.J., Birn H., Nielsen R., et al. The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int. 2002, 62:745-756.
35. Maack T., Johnson V., Kau S.T., et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979, 16:251-270.
36. Norden A.G., Sharratt P., Cutillas P.R., et al. Quantitative amino acid and proteomic analysis: very low excretion of polypeptides >750 Da in normal urine. Kidney Int. 2004, 66:1994-2003.
37. Richter R., Schulz-Knappe P., Schrader M., et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B. Biomed. Sci. Appl. 1999, 726:25-35.
38. Li G., Chu J., Liu X., et al. Separation, identification of uremic middle molecules, and preliminary study on their toxicity. Clin. Chim. Acta 2004, 350:89-98.
39. Kaplan B., Cojocaru M., Unsworth E., et al. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003, 796:141-153.
40. Weissinger E.M., Kaiser T., Meert N., et al. Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol. Dial. Transplant. 2004, 19:3068-3077.
41. Deppisch R.M., Beck W., Goehl H., et al. Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int. Suppl. 2001, 78:S271-S277.
42. Eloot S., Torremans A., De Smet R., et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int. 2005, 67:1566-1575.
43. Marescau B., Nagels G., Possemiers I., et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997, 46:1024-1031.
44. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000, 80:1107-1213.
45. Nakamura K., Ienaga K., Nakano K., et al. Creatol, a creatinine metabolite, as a useful determinant of renal function. Nephron 1994, 66:140-146.
46. Yokozawa T., Fujitsuka N., Oura H. Studies on the precursor of methylguanidine in rats with renal failure. Nephron 1991, 58:90-94.
47. Gonella M., Barsotti G., Lupetti S., et al. Factors affecting the metabolic production of methylguanidine. Clin. Sci. Mol. Med. 1975, 48:341-347.
48. Cohen B.D. Methyl group deficiency and guanidino production in uremia. Mol. Cell. Biochem. 2003, 244:31-36.
49. Aoyagi K., Shahrzad S., Iida S., et al. Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. Kidney Int. Suppl. 2001, 78:S93-S96.
50. Kopple J.D., Gordon S.I., Wang M., et al. Factors affecting serum and urinary guanidinosuccinic acid levels in normal and uremic subjects. J. Lab. Clin. Med. 1977, 90:303-311.
51. Barsotti G., Bevilacqua G., Morelli E., et al. Toxicity arising from guanidine compounds: role of methylguanidine as a uremic toxin. Kidney Int. Suppl. 1975, 299-301.
52. Glorieux G.L., Dhondt A.W., Jacobs P., et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int. 2004, 65:2184-2192.
53. De Deyn P.P., D'Hooge R., Van Bogaert P.P., et al. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int. Suppl. 2001, 78:S77-S83.
54. Siroen M.P., van der Sijp J.R., Teerlink T., et al. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005, 41:559-565.
55. Cooke J.P. Asymmetrical dimethylarginine: the Uber marker?. Circulation 2004, 109:1813-1818.
56. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 2002, 13:170-176.
57. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 2005, 16:2449-2455.
58. Powell G.M., Miller J.J., Olavesen A.H., et al. Liver as major organ of phenol detoxication?. Nature 1974, 252:234-235.
59. Lock E.A., Reed C.J. Xenobiotic metabolizing enzymes of the kidney. Toxicol. Pathol. 1998, 26:18-25.
60. Seligson D. Organic acids in body fluids of the uremic patient. J. Clin. Invest. 1959, 38:1042-1043.
61. Wengle B., Hellstrom K. Volatile phenols in serum of uraemic patients. Clin. Sci. 1972, 43:493-498.
62. Niwa T., Maeda K., Ohki T., et al. Profiling of uremic ultrafiltrate using high resolution gas chromatography-mass spectrometry-identification of 6 polyphenols. Clin. Chim. Acta 1980, 108:113-119.
63. Niwa T., Maeda K., Ohki T., et al. A gas chromatographic-mass spectrometric analysis for phenols in uremic serum. Clin. Chim. Acta 1981, 110:51-57.
64. Schoots A.C., De Vries P.M., Thiemann R., et al. Biochemical and neurophysiological parameters in hemodialyzed patients with chronic renal failure. Clin. Chim. Acta 1989, 185:91-107.
65. Wardle E.N. How toxic are phenols?. Kidney Int. Suppl. 1978, S13-S15.
66. Bammens B., Evenepoel P., Keuleers H., et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006, 69:1081-1087.
67. Armstrong M., Chao F.C., Parker J., et al. Endogenous formation of hippuric acid. Proc. Soc. Exp. Med. Biol. 1955, 90:675-679.
68. Mulder T.P., Rietveld A.G., van Amelsvoort J.M. Consumption of both black tea and green tea results in an increase in the excretion of hippuric acid into urine. Am. J. Clin. Nutr. 2005, 81:256S-260S.
69. Remer T., Manz F. Paleolithic diet, sweet potato eaters, and potential renal acid load. Am. J. Clin. Nutr. 2003, 78:802-803. author reply 803-804.
70. Cathcart-Rake W., Porter R., Whittier F., et al. Effect of diet on serum accumulation and renal excretion of aryl acids and secretory activity in normal and uremic man. Am. J. Clin. Nutr. 1975, 28:1110-1115.
71. Mitch W.E., Brusilow S. Benzoate-induced changes in glycine and urea metabolism in patients with chronic renal failure. J. Pharmacol. Exp. Ther. 1982, 222:572-575.
72. Bammens B., Evenepoel P., Verbeke K., et al. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am. J. Clin. Nutr. 2004, 80:1536-1543.
73. Bammens B., Evenepoel P., Verbeke K., et al. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am. J. Kidney Dis. 2005, 46:512-519.
74. Lesaffer G., De Smet R., Lameire N., et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol. Dial. Transplant. 2000, 15:50-57.
75. De Smet R., Van Kaer J., Van Vlem B., et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin. Chem. 2003, 49:470-478.
76. Meijers B.K., Bammens B., De Moor B., et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 2008, 73:1174-1180.
77. de Loor H., Bammens B., Evenepoel P., et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin. Chem. 2005, 51:1535-1538.
78. Vanholder R., De Smet R., Waterloos M.A., et al. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int. 1995, 47:510-517.
79. Martinez A.W., Recht N.S., Hostetter T.H., et al. Removal of P-cresol sulfate by hemodialysis. J. Am. Soc. Nephrol. 2005, 16:3430-3436.
80. Jones M.R., Kopple J.D., Swendseid M.E. Phenylalanine metabolism in uremic and normal man. Kidney Int. 1978, 14:169-179.
81. Record N.B., Gallagher B.B., Glaser G.H. Phenolic acids in experimental uremia. II. Relationship of phenolic acid structure to seizure threshold in uremia. Arch. Neurol. 1969, 21:395-400.
82. Zimmerman L., Jornvall H., Bergstrom J. Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. Nephron 1990, 55:265-271.
83. Van Haard P., Pavel S. Chromatography of urinary indole derivatives. J. Chromatogr. 1988, 429:59-94.
84. Dou L., Bertrand E., Cerini C., et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004, 65:442-451.
85. Miyazaki T., Aoyama I., Ise M., et al. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol. Dial. Transplant. 2000, 15:1773-1781.
86. Dou L., Jourde-Chiche N., Faure V., et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J. Thromb. Haemost. 2007, 5:1302-1308.
87. Owada S., Goto S., Bannai K., et al. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am. J. Nephrol. 2008, 28:446-454.
88. Shimoishi K., Anraku M., Kitamura K., et al. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm. Res. 2007, 24:1283-1289.
89. Yamamoto H., Tsuruoka S., Ioka T., et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006, 69:1780-1785.
90. Taki K., Tsuruta Y., Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am. J. Nephrol. 2007, 27:30-35.
91. Schulman G., Agarwal R., Acharya M., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am. J. Kidney Dis. 2006, 47:565-577.
92. Saito A., Niwa T., Maeda K., et al. Tryptophan and indolic tryptophan metabolites in chronic renal failure. Am. J. Clin. Nutr. 1980, 33:1402-1406.
93. Ludwig G.D., Senesky D., Bluemle L.W., et al. Indoles in ureamia: identification by countercurrent distribution and paper chromatography. Am. J. Clin. Nutr. 1968, 21:436-450.
94. Saito K., Fujigaki S., Heyes M.P., et al. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am. J. Physiol. Renal Physiol. 2000, 279:F565-F572.
95. Pawlak D., Pawlak K., Malyszko J., et al. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int. Urol. Nephrol. 2001, 33:399-404.
96. Simenhoff M.L., Asatoor A.M., Milne M.D., et al. Retention of aliphatic amines in uraemia. Clin. Sci. 1963, 25:65-77.
97. Baba S., Watanabe Y., Gejyo F., et al. High-performance liquid chromatographic determination of serum aliphatic amines in chronic renal failure. Clin. Chim. Acta 1984, 136:49-56.
98. Smith J.L., Wishnok J.S., Deen W.M. Metabolism and excretion of methylamines in rats. Toxicol. Appl. Pharmacol. 1994, 125:296-308.
99. Ihle B.U., Cox R.W., Dunn S.R., et al. Determination of body burden of uremic toxins. Clin. Nephrol. 1984, 22:82-89.
100. Wright S.H., Dantzler W.H. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 2004, 84:987-1049.
101. Roch-Ramel F., Besseghir K., Murer H. Renal excretion and tubular transport of organic anions and cations. Handbook of Physiology. Section 8: Renal Physiology 1992, vol. 8:2189-2262. Oxford University Press, New York. E.E. Windhager (Ed.).
102. Shim C.K., Sawada Y., Iga T., et al. Estimation of renal secretory function for organic cations by endogenous N1-methylnicotinamide in rats with experimental renal failure. J. Pharmacokinet. Biopharm. 1984, 12:23-42.
103. Zeisel S.H., Wishnok J.S., Blusztajn J.K. Formation of methylamines from ingested choline and lecithin. J. Pharmacol. Exp. Ther. 1983, 225:320-324.
104. Zhang A.Q., Mitchell S.C., Ayesh R., et al. Dimethylamine formation in man. Biochem. Pharmacol. 1993, 45:2185-2188.
105. Zhang A.Q., Mitchell S.C., Smith R.L. Dietary precursors of trimethylamine in man: a pilot study. Food Chem. Toxicol. 1999, 37:515-520.
106. Simenhoff M.L., Saukkonen J.J., Burke J.F., et al. Bacterial populations of the small intestine in uremia. Nephron 1978, 22:63-68.
107. Simenhoff M.L., Ginn H.E., Teschan P.E. Toxicity of aliphatic amines in uremia. Trans. Am. Soc. Artif. Intern. Organs 1977, 23:560-565.
108. Simenhoff M.L., Saukkonen J.J., Burke J.F., et al. Importance of aliphatic amines in uremia. Kidney Int. Suppl. 1978, S16-S19.
109. Simenhoff M.L., Saukkonen J.J., Burke J.F., et al. Amine metabolism and the small bowel in uraemia. Lancet 1976, 2:818-821.
110. Mitchell S.C., Zhang A.Q. Methylamine in human urine. Clin. Chim. Acta 2001, 312:107-114.
111. Simenhoff M.L., Burke J.F., Saukkonen J.J., et al. Biochemical profile or uremic breath. N. Engl. J. Med. 1977, 297:132-135.
112. Pirisino R., Ghelardini C., Banchelli G., et al. Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aODN towards Kv1.1 channels. Br. J. Pharmacol. 2001, 134:880-886.
113. Pirisino R., Ghelardini C., De Siena G., et al. Methylamine: a new endogenous modulator of neuron firing?. Med. Sci. Monit. 2005, 11:RA257-RA261.
114. Pirisino R., Ghelardini C., Pacini A., et al. Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain Kv1.6 channel subtype. Br. J. Pharmacol. 2004, 142:381-389.
115. Yu P.H., Wright S., Fan E.H., et al. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochem. Biophys. Acta 2003, 1647:193-199.
116. Sato M., Koyama M., Miyazaki T., et al. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients. Nephron 1996, 74:419-421.
117. Niwa T., Takeda N., Maeda K., et al. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clin. Chim. Acta 1988, 173:127-138.
118. Takamura N., Maruyama T., Otagiri M. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia. Clin. Chem. 1997, 43:2274-2280.
119. Costigan M.G., Callaghan C.A., Lindup W.E. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure?. Nephron 1996, 73:169-173.
120. Niwa T., Yamamoto N., Maeda K., et al. Gas chromatographic-mass spectrometric analysis of polyols in urine and serum of uremic patients. Identification of new deoxyalditols and inositol isomers. J. Chromatogr. 1983, 277:25-39.
121. Niwa T., Tohyama K., Kato Y. Analysis of polyols in uremic serum by liquid chromatography combined with atmospheric pressure chemical ionization mass spectrometry. J. Chromatogr. 1993, 613:9-14.
122. Niwa T., Sobue G., Maeda K., et al. Myoinositol inhibits proliferation of cultured Schwann cells: evidence for neurotoxicity of myoinositol. Nephrol. Dial. Transplant. 1989, 4:662-666.
123. Niwa T., Takeda N., Yoshizumi H. RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int. 1998, 53:1801-1806.
124. Daniewska-Michalska D., Motyl T., Gellert R., et al. Efficiency of hemodialysis of pyrimidine compounds in patients with chronic renal failure. Nephron 1993, 64:193-197.
125. Mydlik M., Derzsiova K. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure. Kidney Int. Suppl. 2001, 78:S304-S307.
126. Holmes R.P., Goodman H.O., Assimos D.G. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001, 59:270-276.
127. Saito A., Takagi T., Chung T.G., et al. Serum levels of polyamines in patients with chronic renal failure. Kidney Int. Suppl. 1983, 16:S234-S237.
128. Igarashi K., Ueda S., Yoshida K., et al. Polyamines in renal failure. Amino Acids 2006, 31:477-483.
129. Yokoyama K., Tajima M., Yoshida H., et al. Plasma pteridine concentrations in patients with chronic renal failure. Nephrol. Dial. Transplant. 2002, 17:1032-1036.
130. Williams R.H., Shaykh M., Ahmed S., et al. Purification and biochemical characterization of xanthopterin from patients with chronic renal failure. I. Isolation, purification and preliminary characterization. Clin. Biochem. 1991, 24:399-406.
131. Babb A.L., Ahmad S., Bergstrom J., et al. The middle molecule hypothesis in perspective. Am. J. Kidney Dis. 1981, 1:46-50.
132. Babb A.L., Farrell P.C., Uvelli D.A., et al. Hemodialyzer evaluation by examination of solute molecular spectra. Trans. Am. Soc. Artif. Intern. Organs 1972, 18:98-105. 122.
133. Henderson L.W., Colton C.K., Ford C.A., et al. Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. 1975. J. Am. Soc. Nephrol. 1997, 8:494-508. discussion 494-495, 497-500.
134. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002, 347:2010-2019.
135. Cheung A.K., Rocco M.V., Yan G., et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J. Am. Soc. Nephrol. 2006, 17:546-555.
136. Gulyassy P.F. Can dialysis remove protein bound toxins that accumulate because of renal secretory failure?. ASAIO J. 1994, 40:92-94.
137. Peters T. Ligand binding by albumin. All about albumin 1996, 79-132. Academic Press, San Diego.
138. Gulyassy P.F., Depner T.A. Impaired binding of drugs and endogenous ligands in renal diseases. Am. J. Kidney Dis. 1983, 2:578-601.
139. Gulyassy P.F., Bottini A.T., Stanfel L.A., et al. Isolation and chemical identification of inhibitors of plasma ligand binding. Kidney Int. 1986, 30:391-398.
140. Ohtsuki S., Asaba H., Takanaga H., et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J. Neurochem. 2002, 83:57-66.
141. Meyer T.W., Peattie J.W., Miller J.D., et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J. Am. Soc. Nephrol. 2007, 18:868-874.
142. Meijers B.K., Weber V., Bammens B., et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif. Organs 2008, 32:214-219.
143. Bammens B., Evenepoel P., Verbeke K., et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003, 64:2238-2243.
144. Pham N.M., Recht N.S., Hostetter T.H., et al. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin. J. Am. Soc. Nephrol. 2008, 3:85-90.
145. Schneditz D., Daugirdas J.T. Compartment effects in hemodialysis. Sem. Dial. 2001, 14:271-277.
146. Heaf J.G., Jensen S.B., Jensen K., et al. The cellular clearance theory does not explain the post-dialytic small molecule rebound. Scand. J. Urol. Nephrol. 1998, 32:350-355.
147. Ziolko M., Pietrzyk J.A., Grabska-Chrzastowska J. Accuracy of hemodialysis modeling. Kidney Int. 2000, 57:1152-1163.
148. Charra B., Terrat J.C., Vanel T., et al. Long thrice weekly hemodialysis: the Tassin experience. Int. J. Artif. Organs 2004, 27:265-283.
149. Kopple J.D., Greene T., Chumlea W.C., et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int. 2000, 57:1688-1703.
150. Giovannetti S., Maggiore Q. A low-nitrogen diet with proteins of high biological value for severe chronic uraemia. Lancet 1964, 37:1000-1003.
151. Cohen B.D. Guanidinosuccinic acid in uremia. Arch. Intern. Med. 1970, 126:847-850.
152. Ando A., Orita Y., Nakata K., et al. Effect of low protein diet and surplus of essential amino acids on the serum concentration and the urinary excretion of methylguanidine and guanidinosuccinic acid in chronic renal failure. Nephron 1979, 24:161-169.
153. Niwa T., Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 1994, 124:96-104.
154. Beier R.C. Natural pesticides and bioactive components in foods. Rev. Environ. Contam. Toxicol. 1990, 113:47-137.
155. Bammens B., Verbeke K., Vanrenterghem Y., et al. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int. 2003, 64:2196-2203.
156. Hida M., Aiba Y., Sawamura S., et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996, 74:349-355.
157. Jonker J.W., Wagenaar E., Van Eijl S., et al. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell. Biol. 2003, 23:7902-7908.
158. Eraly S.A., Vallon V., Vaughn D.A, et al. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J. Biol. Chem. 2006, 281:5072-5083.
159. Himmelfarb J., Stenvinkel P., Ikizler T.A., et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62:1524-1538.
160. Capeillere-Blandin C., Gausson V., Descamps-Latscha B., et al. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim. Biophys. Acta 2004, 1689:91-102.
161. Himmelfarb J., McMonagle E., McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 2000, 58:2571-2578.
162. Himmelfarb J., McMenamin E., McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int. 2002, 61:705-716.
163. Miyata T., Sugiyama S., Saito A., et al. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int. Suppl. 2001, 78:S25-S31.
164. Meerwaldt R., Hartog J.W., Graaff R., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005, 16:3687-3693.
165. Schwedler S.B., Metzger T., Schinzel R., et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002, 62:301-310.
166. Miyata T., Ueda Y., Saito A., et al. Carbonyl stress and dialysis-related amyloidosis. Nephrol. Dial. Transplant. 2000, 15(Suppl. 1):25-28.
167. Wang Z., Nicholls S.J., Rodriguez E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 2007, 13:1176-1184.
168. Monteon F.J., Laidlaw S.A., Shaib J.K., et al. Energy expenditure in patients with chronic renal failure. Kidney Int. 1986, 30:741-747.
169. Veeneman J.M., Kingma H.A., Stellaard F., et al. Oxidative metabolism appears to be reduced in long-term hemodialysis patients. Am. J. Kidney Dis. 2005, 46:102-110.
170. Panesar A., Agarwal R. Resting energy expenditure in chronic kidney disease: relationship with glomerular filtration rate. Clin. Nephrol. 2003, 59:360-366.
171. Ikizler T.A., Wingard R.L., Sun M., et al. Increased energy expenditure in hemodialysis patients. J. Am. Soc. Nephrol. 1996, 7:2646-2653.
172. Avesani C.M., Draibe S.A., Kamimura M.A., et al. Decreased resting energy expenditure in non-dialysed chronic kidney disease patients. Nephrol. Dial. Transplant. 2004, 19:3091-3097.
173. Wang A.Y., Sea M.M., Tang N., et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J. Am. Soc. Nephrol. 2004, 15:3134-3143.
174. Leibel R.L., Rosenbaum M., Hirsch J. Changes in energy expenditure resulting from altered body weight. N. Engl. J. Med. 1995, 332:621-628.
175. Hohenegger M., Vermes M., Esposito R., et al. Effect of some uremic toxins on oxygen consumption of rats in vivo and in vitro. Nephron 1988, 48:154-158.
176. Kurnik B.R., Weisberg L.S., Kurnik P.B. Renal and systemic oxygen consumption in patients with normal and abnormal renal function. J. Am. Soc. Nephrol. 1992, 2:1617-1626.
177. Rigalleau V., Gin H. Carbohydrate metabolism in uraemia. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:463-469.
178. Kobayashi S., Maesato K., Moriya H., et al. Insulin resistance in patients with chronic kidney disease. Am. J. Kidney Dis. 2005, 45:275-280.
179. Sechi L.A., Catena C., Zingaro L., et al. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002, 51:1226-1232.
180. Maloff B.L., McCaleb M.L., Lockwood D.H. Cellular basis of insulin resistance in chronic uremia. Am. J. Physiol. 1983, 245:E178-E184.
181. Smith D., DeFronzo R.A. Insulin resistance in uremia mediated by post-binding defects. Kidney Int. 1982, 22:54-62.
182. Axelsson J., Bergsten A., Qureshi A.R., et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006, 69:596-604.
183. Okada K., Takahashi Y., Okawa E., et al. Relationship between insulin resistance and uremic toxins in the gastrointestinal tract. Nephron 2001, 88:384-386.
184. Reaich D., Channon S.M., Scrimgeour C.M., et al. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am. J. Physiol. 1993, 265:E230-E235.
185. Wojtaszewski J.F., Jorgensen S.B., Frosig C., et al. Insulin signalling: effects of prior exercise. Acta Physiol. Scand. 2003, 178:321-328.
186. Mustata S., Chan C., Lai V., et al. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J. Am. Soc. Nephrol. 2004, 15:2713-2718.
187. Shinohara K., Shoji T., Emoto M., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002, 13:1894-1900.
188. DeFronzo R.A. Insulin and renal sodium handling: clinical implications. Int. J. Obes. 1981, 5(Suppl. 1):93-104.
189. Brands M.W., Hall J.E., Keen H.L. Is insulin resistance linked to hypertension?. Clin. Exp. Pharmacol. Physiol. 1998, 25:70-76.
190. Kobayashi S., Oka M., Maesato K., et al. Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin. J. Am. Soc. Nephrol. 2008, 3:1289-1295.
191. Lim V.S., Kopple J.D. Protein metabolism in patients with chronic renal failure: role of uremia and dialysis. Kidney Int. 2000, 58:1-10.
192. Adrogue H.J. Glucose homeostasis and the kidney. Kidney Int. 1992, 42:1266-1282.
193. Owen O.E., Felig P., Morgan A.P., et al. Liver and kidney metabolism during prolonged starvation. J. Clin. Invest. 1969, 48:574-583.
194. Cersosimo E., Judd R.L., Miles J.M. Insulin regulation of renal glucose metabolism in conscious dogs. J. Clin. Invest. 1994, 93:2584-2589.
195. Don B.R., Kaysen G. Serum albumin: relationship to inflammation and nutrition. Sem. Dialysis 2004, 17:432-437.
196. Kopple J.D., Jones M., Fukuda S., et al. Amino acid and protein metabolism in renal failure. Am. J. Clin. Nutr. 1978, 31:1532-1540.
197. Laidlaw S.A., Berg R.L., Kopple J.D., et al. Patterns of fasting plasma amino acid levels in chronic renal insufficiency: results from the feasibility phase of the Modification of Diet in Renal Disease Study. Am. J. Kidney Dis. 1994, 23:504-513.
198. Ceballos I., Chauveau P., Guerin V., et al. Early alterations of plasma free amino acids in chronic renal failure. Clin. Chim. Acta 1990, 188:101-108.
199. Francis M.E., Eggers P.W., Hostetter T.H., et al. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int. 2004, 66:303-312.
200. Graham K.A., Reaich D., Channon S.M., et al. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int. 1996, 49:1396-1400.
201. Graham K.A., Reaich D., Channon S.M., et al. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J. Am. Soc. Nephrol. 1997, 8:632-637.
202. Bailey J.L., Zheng B., Hu Z., et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J. Am. Soc. Nephrol. 2006, 17:1388-1394.
203. Mitch W.E., Du J. Cellular mechanisms causing loss of muscle mass in kidney disease. Sem. Nephrol. 2004, 24:484-487.
204. Sahadevan M., Kasiske B.L. Hyperlipidemia in kidney disease: causes and consequences. Curr. Opin. Nephrol. Hypertens. 2002, 11:323-329.
205. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005, 353:238-248.
206. Walters B.A., Hays R.D., Spritzer K.L., et al. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am. J. Kidney Dis. 2002, 40:1185-1194.
207. Rocco M.V., Gassman J.J., Wang S.R., et al. Cross-sectional study of quality of life and symptoms in chronic renal disease patients: the Modification of Diet in Renal Disease Study. Am. J. Kidney Dis. 1997, 29:888-896.
208. Perlman R.L., Finkelstein F.O., Liu L., et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am. J. Kidney Dis. 2005, 45:658-666.
209. Wu A.W., Fink N.E., Marsh-Manzi J.V., et al. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. J. Am. Soc. Nephrol. 2004, 15:743-753.
210. Beusterien K.M., Nissenson A.R., Port F.K., et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J. Am. Soc. Nephrol. 1996, 7:763-773.
211. Kimmel P.L., Patel S.S. Quality of life in patients with chronic kidney disease: focus on end-stage renal disease treated with hemodialysis. Sem. Nephrol. 2006, 26:68-79.
212. Johansen K.L. Physical functioning and exercise capacity in patients on dialysis. Adv. Ren. Replace. Ther. 1999, 6:141-148.
213. Painter P. Physical functioning in end-stage renal disease patients: update 2005. Hemodial. Int. 2005, 9:218-235.
214. Johansen K.L., Doyle J., Sakkas G.K., et al. Neural and metabolic mechanisms of excessive muscle fatigue in maintenance hemodialysis patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289:R805-R813.
215. Blake C., O'Meara Y.M. Subjective and objective physical limitations in high-functioning renal dialysis patients. Nephrol. Dial. Transplant. 2004, 19:3124-3129.
216. Clyne N., Esbjornsson M., Jansson E., et al. Effects of renal failure on skeletal muscle. Nephron 1993, 63:395-399.
217. Heiwe S., Clyne N., Tollback A., et al. Effects of regular resistance training on muscle histopathology and morphometry in elderly patients with chronic kidney disease. Am. J. Phys. Med. Rehabil. 2005, 84:865-874.
218. Brouns R., De Deyn P.P. Neurological complications in renal failure: a review. Clin. Neurol. Neurosurg. 2004, 107:1-16.
219. Krishnan A.V., Phoon R.K., Pussell B.A., et al. Altered motor nerve excitability in end-stage kidney disease. Brain 2005, 128:2164-2174.
220. Pereira A.A., Weiner D.E., Scott T., et al. Cognitive function in dialysis patients. Am. J. Kidney Dis. 2005, 45:448-462.
221. Kurella M., Chertow G.M., Fried L.F., et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 2005, 16:2127-2133.
222. Kurella M., Yaffe K., Shlipak M.G., et al. Chronic kidney disease and cognitive impairment in menopausal women. Am. J. Kidney Dis. 2005, 45:66-76.
223. Hailpern S.M., Melamed M.L., Cohen H.W., et al. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 2007, 18:2205-2213.
224. Seliger S.L., Longstreth W.T., Katz R., et al. Cystatin C and subclinical brain infarction. J. Am. Soc. Nephrol. 2005, 16:3721-3727.
225. Mitch W.E. Cachexia in chronic kidney disease: a link to defective central nervous system control of appetite. J. Clin. Invest. 2005, 115:1476-1478.
226. Cheung W., Yu P.X., Little B.M., et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J. Clin. Invest. 2005, 115:1659-1665.
227. Bergstrom J. Regulation of appetite in chronic renal failure. Miner. Electrolyte Metab. 1999, 25:291-297.
228. Griep M.I., Van der Niepen P., Sennesael J.J., et al. Odour perception in chronic renal disease. Nephrol. Dial. Transplant. 1997, 12:2093-2098.
229. Middleton R.A., Allman-Farinelli M.A. Taste sensitivity is altered in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis. J. Nutr. 1999, 129:122-125.
230. Fernstrom A., Hylander B., Rossner S. Taste acuity in patients with chronic renal failure. Clin. Nephrol. 1996, 45:169-174.
231. Raff A.C., Lieu S., Melamed M.L., et al. Relationship of impaired olfactory function in ESRD to malnutrition and retained uremic molecules. Am. J. Kidney Dis. 2008, 52:102-110.
232. Welt L.G., Sachs J.R., McManus T.J. An ion transport defect in erythrocytes from uremic patients. Trans. Assoc. Am. Physicians 1964, 77:169-181.
233. Kaji D., Thomas K. Na+-K+ pump in chronic renal failure. Am. J. Physiol. 1987, 252:F785-F793.
234. Komiyama Y., Dong X.H., Nishimura N., et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin. Biochem. 2005, 38:36-45.
235. Kennedy D.J., Vetteth S., Periyasamy S.M., et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006, 47:488-495.
236. Murrell J.R., Randall J.D., Rosoff J., et al. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 2005, 112:1301-1308.
237. Dmitrieva R.I., Lalli E., Doris P.A. Regulation of adrenocortical cardiotonic steroid production by dopamine and PKA signaling. Front. Biosci. 2005, 10:2489-2495.
238. Dostanic-Larson I., Lorenz J.N., Van Huysse J.W., et al. Physiological role of the alpha1- and alpha2-isoforms of the Na+-K+-ATPase and biological significance of their cardiac glycoside binding site. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R524-R528.
239. Buckalew V.M. Endogenous digitalis-like factors. A historical overview. Front. Biosci. 2005, 10:2325-2334.
240. Cotton J.R., Woodard T., Carter N.W., et al. Resting skeletal muscle membrane potential as an index of uremic toxicity. A proposed new method to assess adequacy of hemodialysis. J. Clin. Invest. 1979, 63:501-506.